Sycomore Asset Management
AZN icon

Sycomore Asset Management’s AstraZeneca AZN Stock Holding History

Sycomore Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30.4M Hold
163,871
– – 3.31% 6
2026
Q2 		$30.6M Hold
163,871
– – 3.29% 6
2026
Q1 		$26.2M Buy
+163,871
New +$31.6M 3.65% 4

Other funds holding AZN

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $162B AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Sycomore Asset Management's AZN Position: Q3 2026 in Review

Sycomore Asset Management held its AstraZeneca (AZN) position steady in Q3 2026 at 163,871 shares worth $30.4M. The position accounts for 3.31% of the portfolio, ranked #6.

Sycomore Asset Management first reported a position in AZN in Q1 2026 and has held it in 3 quarters since. The position peaked at $30.6M in Q2 2026. 1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Sycomore Asset Management held 163,871 shares of AstraZeneca worth $30.4M as of Q3 2026.
  • Sycomore Asset Management left its AstraZeneca share count unchanged in Q3 2026.
  • AstraZeneca made up 3.31% of Sycomore Asset Management's portfolio in Q3 2026, its #6 holding.
  • Sycomore Asset Management first reported a position in AstraZeneca in Q1 2026 and has held it in 3 quarters since.
  • Sycomore Asset Management's AstraZeneca position peaked at $30.6M in Q2 2026.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Sycomore Asset Management's 13F filing for Q3 2026, filed 26 Oct 2026.